Cargando…

Antitumor Effects of PRMT5 Inhibition in Sarcomas

Patients with advanced soft-tissue sarcomas (STS) have few therapeutic options. Protein arginine methyltransferase 5 (PRMT5), an anticancer target, has been extensively investigated in recent years in epithelial tumors. To date, no data related to the biological role of PRMT5 inhibition and its pote...

Descripción completa

Detalles Bibliográficos
Autores principales:	Verbeke, Stéphanie, Bourdon, Aurélien, Guegan, Jean-Philippe, Leroy, Laura, Chaire, Vanessa, Richard, Elodie, Bessede, Alban, Italiano, Antoine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10621483/ https://www.ncbi.nlm.nih.gov/pubmed/37861293 http://dx.doi.org/10.1158/2767-9764.CRC-23-0239

Ejemplares similares

ATR Inhibition Broadly Sensitizes Soft-Tissue Sarcoma Cells to Chemotherapy Independent of Alternative Lengthening Telomere (ALT) Status
por: Laroche-Clary, Audrey, et al.
Publicado: (2020)

Targeting Tryptophan Catabolism in Cancer Immunotherapy Era: Challenges and Perspectives
por: Peyraud, Florent, et al.
Publicado: (2022)

Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma
por: Toulmonde, Maud, et al.
Publicado: (2022)

Phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced breast cancer
por: Cousin, Sophie, et al.
Publicado: (2022)

Pembrolizumab combined with low-dose cyclophosphamide and intra-tumoral injection of the toll-like receptor 4 agonist G100 in patients with advanced pretreated soft tissue sarcoma: results from the PEMBROSARC basket study
por: Spalato-Ceruso, Mariella, et al.
Publicado: (2022)

GSK3-beta as a candidate therapeutic target in soft tissue sarcomas
por: Verbeke, S., et al.
Publicado: (2021)

PRIMA-1(MET) induces death in soft-tissue sarcomas cell independent of p53
por: Grellety, Thomas, et al.
Publicado: (2015)

Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas
por: Laroche, Audrey, et al.
Publicado: (2017)

Genome-wide CRISPR/Cas9 library screening identified ATM signaling network genes as critical drivers for resistance to ATR inhibition in soft-tissue sarcomas: synthetic lethality and therapeutic implications
por: Spalato-Ceruso, M, et al.
Publicado: (2023)

Upregulation of Indoleamine 2,3-Dioxygenase 1 in Tumor Cells and Tertiary Lymphoid Structures is a Hallmark of Inflamed Non–Small Cell Lung Cancer
por: Bessede, Alban, et al.
Publicado: (2023)

PRMT1 loss sensitizes cells to PRMT5 inhibition
por: Gao, Guozhen, et al.
Publicado: (2019)

MDM2 antagonists synergize with PI3K/mTOR inhibition in well-differentiated/dedifferentiated liposarcomas
por: Laroche, Audrey, et al.
Publicado: (2017)

Heterogeneous Mechanisms of Secondary Resistance and Clonal Selection in Sarcoma during Treatment with Nutlin
por: Laroche, Audrey, et al.
Publicado: (2015)

Inactivating mutations in genes encoding for components of the BAF/PBAF complex and immune-checkpoint inhibitor outcome
por: Courtet, Kevin, et al.
Publicado: (2020)

Targeting epigenetics in sarcomas through EZH2 inhibition
por: Italiano, Antoine
Publicado: (2020)

IDO Targeting in Sarcoma: Biological and Clinical Implications
por: Nafia, Imane, et al.
Publicado: (2020)

Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications
por: Fourneaux, Benjamin, et al.
Publicado: (2016)

Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodies
por: Larroquette, Mathieu, et al.
Publicado: (2022)

Tadalafil increases the antitumor activity of 5-FU through inhibiting PRMT5-mediated glycolysis and cell proliferation in colorectal cancer
por: Shen, Yao, et al.
Publicado: (2022)

PRMT5 inhibition disrupts splicing and stemness in glioblastoma
por: Sachamitr, Patty, et al.
Publicado: (2021)

High throughput profiling of undifferentiated pleomorphic sarcomas identifies two main subgroups with distinct immune profile, clinical outcome and sensitivity to targeted therapies
por: Toulmonde, Maud, et al.
Publicado: (2020)

Identifying and targeting cancer stem cells in leiomyosarcoma: prognostic impact and role to overcome secondary resistance to PI3K/mTOR inhibition
por: Fourneaux, Benjamin, et al.
Publicado: (2019)

BRCA1 haplotype and clinical benefit of trabectedin in soft-tissue sarcoma patients
por: Laroche-Clary, A, et al.
Publicado: (2015)

Expression of Concern to: Identifying and targeting cancer stem cells in leiomyosarcoma: prognostic impact and role to overcome secondary resistance to PI3K/mTOR inhibition
por: Fourneaux, Benjamin, et al.
Publicado: (2019)

Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas
por: Laroche-Clary, Audrey, et al.
Publicado: (2017)

The Methyltransferases PRMT4/CARM1 and PRMT5 Control Differentially Myogenesis in Zebrafish
por: Batut, Julie, et al.
Publicado: (2011)

Protein arginine methyltransferases PRMT1, PRMT4/CARM1 and PRMT5 have distinct functions in control of osteoblast differentiation
por: Dashti, Parisa, et al.
Publicado: (2023)

PRMT5 inhibitors on the (myeloma) road
por: Gulla, Annamaria, et al.
Publicado: (2018)

PRMT5 prognostic value in cancer
por: Lattouf, Hanine, et al.
Publicado: (2019)

PRMT5 function and targeting in cancer
por: Kim, Hyungsoo, et al.
Publicado: (2020)

The Role of PRMT5 in Immuno-Oncology
por: Abe, Yoshinori, et al.
Publicado: (2023)

High Prevalence of 5T4/Trophoblast Glycoprotein in Soft Tissue Sarcomas
por: Groothuis, Patrick, et al.
Publicado: (2021)

Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor Activity
por: Brehmer, Dirk, et al.
Publicado: (2021)

Regulation of a PRMT5/NF-κB Axis by Phosphorylation of PRMT5 at Serine 15 in Colorectal Cancer
por: Hartley, Antja-Voy, et al.
Publicado: (2020)

PRMT5-mediated regulation of developmental myelination
por: Scaglione, Antonella, et al.
Publicado: (2018)

PRMT5 in gene regulation and hematologic malignancies
por: Zhu, Fen, et al.
Publicado: (2019)

The Structure and Functions of PRMT5 in Human Diseases
por: Motolani, Aishat, et al.
Publicado: (2021)

PRMT5: An Emerging Target for Pancreatic Adenocarcinoma
por: Lee, Michael K. C., et al.
Publicado: (2021)

PRMT5 disruption drives antitumor immunity in cervical cancer by reprogramming T cell-mediated response and regulating PD-L1 expression
por: Jiang, Yongshuai, et al.
Publicado: (2021)

Protein arginine methyltransferase 5 (PRMT5) dysregulation in cancer
por: Shailesh, Harshita, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_jbn8m2gn2j8fkl3fv9bu2q7lbh